Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Chief Operating Officer | September 03, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-03 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. Row 2 · 2026-09-03 · Sale · Disposed 10,000 · Balance 0 F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.95 · Expires 2029-03-19 | Direct | 104,954 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Exercise / conversion · Disposed 10,000 · Balance 104,954 F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2: Such transaction was pursuant to a pre-approved 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
F2: Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 23:09 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001193125-26-382277 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,954 Underlying: Common Stock · 10,000 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 23:09 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 10,000 | $208.65 | $2,086,500.00 |
DisclosureSEC source: 0001193125-26-382277 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 23:09 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 10,000 | $12.95 | $129,500.00 |
DisclosureSEC source: 0001193125-26-382277 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 05, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 233 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · derivative · entry 6 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,954 Underlying: Common Stock · 233 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| May 05, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 233 | $228.18 | $53,165.94 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 4 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.01 and $230.77. Read SEC document |
| May 05, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 233 | $12.95 | $3,017.35 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| May 04, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,517 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · derivative · entry 5 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,187 Underlying: Common Stock · 4,517 shares Expires 2029-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| May 04, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 4,517 | $227.94 | $1,029,604.98 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $225.12 and $231.97. Read SEC document |
| May 04, 2026 Filed May 6, 2026 00:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 4,517 | $12.95 | $58,495.15 |
DisclosureSEC source: 0001193125-26-207148 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. Read SEC document |
| April 21, 2026 Filed Apr 24, 2026 01:02 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 8,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-174419 · ownership.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,669 Underlying: Common Stock · 8,669 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. F2 · derivative.expiration_date: Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:10 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 19,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-083605 · ownership.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,663 Underlying: Common Stock · 19,663 shares Expires 2036-02-26 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 26, 2030. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's 2025 Long-Term Incentive Plan ("2025 Plan")), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the 2025 Plan), or termination due to death or Total and Permanent Disability (as defined in the 2025 Plan)), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,378 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001193125-26-083586 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,378 shares Expires 2028-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 35,378 | $161.88 | $5,726,990.64 |
DisclosureSEC source: 0001193125-26-083586 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.10 and $163.42. Read SEC document |
| February 26, 2026 Filed Feb 28, 2026 00:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 35,378 | $2.85 | $100,827.30 |
DisclosureSEC source: 0001193125-26-083586 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| September 22, 2025 Filed Sep 22, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001193125-25-211788 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,378 Underlying: Common Stock · 10,000 shares Expires 2028-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| September 22, 2025 Filed Sep 22, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 10,000 | $115.96 | $1,159,600.00 |
DisclosureSEC source: 0001193125-25-211788 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $115.11 and $116.55. Read SEC document |
| September 22, 2025 Filed Sep 22, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0001193125-25-211788 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · derivative · entry 6 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · derivative · entry 5 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 40,000 | $114.23 | $4,569,200.00 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 4 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F4 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F6 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $112.93 and $116.87. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 15,000 | $4.85 | $72,750.00 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 25,000 | $4.95 | $123,750.00 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 5,783 | $116.19 | $671,926.77 |
DisclosureSEC source: 0001193125-25-206494 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents the sale of underlying shares of previously exercised stock options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F5 · price: Represents the sale price of all shares in an open market transaction. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0000950170-25-084556 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 25,000 | $110.44 | $2,761,000.00 |
DisclosureSEC source: 0000950170-25-084556 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,783 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 23:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 25,000 | $8.02 | $200,500.00 |
DisclosureSEC source: 0000950170-25-084556 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 28, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · derivative · entry 6 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 28, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 20,000 | $103.45 | $2,069,000.00 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 4 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,783 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F5 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.67 and $104.22. Read SEC document |
| May 28, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 20,000 | $6.47 | $129,400.00 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 27, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,673 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · derivative · entry 5 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,673 shares Expires 2025-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 27, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 20,673 | $104.66 | $2,163,636.18 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,783 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $103.96 and $106.44. Read SEC document |
| May 27, 2025 Filed May 29, 2025 01:52 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 20,673 | $6.47 | $133,754.31 |
DisclosureSEC source: 0000950170-25-078552 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 00:53 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantPerformance Stock Units · Derivative | 10,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,769 Underlying: Common Stock · 10,769 shares Expires not disclosed F4 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. F5 · derivative.expiration_date: Each PSU will vest upon achievement of certain financial, regulatory and developmental performance milestones, subject to the reporting person's continued service as of each vesting date. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:53 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 10,769 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,769 Underlying: Common Stock · 10,769 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on February 21, 2029. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 00:53 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,875 | $0.00 Strike: $137.75 | $0.00 |
DisclosureSEC source: 0000950170-25-027065 · ownership.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,875 Underlying: Common Stock · 10,875 shares Expires 2035-02-20 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 21, 2029. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:27 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,739 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-24-094967 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,739 shares Expires 2024-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:27 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 47,739 | $84.26 | $4,022,488.14 |
DisclosureSEC source: 0000950170-24-094967 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,783 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. F4 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $82.705 and $85.975. Read SEC document |
| August 09, 2024 Filed Aug 9, 2024 23:27 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 47,739 | $4.04 | $192,865.56 |
DisclosureSEC source: 0000950170-24-094967 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this year. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| May 29, 2024 Filed May 30, 2024 00:12 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,693 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000950170-24-066177 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,693 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. Read SEC document |
| May 29, 2024 Filed May 30, 2024 00:12 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 7,910 | $74.31 | $587,813.46 |
DisclosureSEC source: 0000950170-24-066177 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 F2 · kind: Represents the subsequent sale of a portion of the underlying shares of the aforementioned exercise of stock options by the reporting person through a "sell to cover" transaction to satisfy tax withholding obligations and costs in connection with the aforementioned exercise of stock options. F3 · price: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $73.99 and $74.52. Read SEC document |
| May 29, 2024 Filed May 30, 2024 00:12 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 13,693 | $1.30 | $17,800.90 |
DisclosureSEC source: 0000950170-24-066177 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options prior to the 10-year expiration date of such options. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,662 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000950170-24-039617 · ownership.xml · derivative · entry 3 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,662 shares Expires 2024-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options immediately prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | SaleCommon Stock | 24,662 | $77.24 | $1,904,942.20 |
DisclosureSEC source: 0000950170-24-039617 · ownership.xml · nonDerivative · entry 2 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. F3 · kind: Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 22:46 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | Exercise / conversionCommon Stock | 24,662 | $1.30 | $32,060.60 |
DisclosureSEC source: 0000950170-24-039617 · ownership.xml · nonDerivative · entry 1 Jacobson Mark L. · CIK 0001805812 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an exercise of stock options immediately prior to the 10-year expiration date of such options. F2 · kind: Such transaction was pursuant to a pre-approved 10b5-1 plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 18,027 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023373 · ownership.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,027 Underlying: Common Stock · 18,027 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on February 27, 2028. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:34 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 32,825 | $0.00 Strike: $84.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023373 · ownership.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,825 Underlying: Common Stock · 32,825 shares Expires 2034-02-26 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on February 27, 2028. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:15 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 23,491 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016458 · doc4.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 2, 2027. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:15 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 41,424 | $0.00 Strike: $65.32 | $0.00 |
DisclosureSEC source: 0001209191-23-016458 · doc4.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,424 Underlying: Common Stock · 41,424 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 2, 2027. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:03 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantRestricted Stock Units · Derivative | 47,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017159 · doc4.xml · derivative · entry 2 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,990 Underlying: Common Stock · 47,990 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. F3 · derivative.expiration_date: 25% of the RSUs will vest on the one (1) year anniversary of the date of grant. The remaining RSUs will vest in in three substantially equal annual installments, such that the RSUs will be fully vested on March 4, 2026. Vested shares will be delivered to the reporting person upon the earlier of (i) the closing of a Change in Control (as defined in the Issuer's Amended and Restated 2015 Omnibus Incentive Compensation Plan (the "Plan"), (ii) the reporting person's separation of service from the Issuer (including termination with or without Cause (as defined in the Plan), or termination due to death or disability), or (iii) seven (7) years from the date of grant. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:03 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 89,405 | $0.00 Strike: $29.91 | $0.00 |
DisclosureSEC source: 0001209191-22-017159 · doc4.xml · derivative · entry 1 Jacobson Mark L. · CIK 0001805812 · CHIEF OPERATING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,405 Underlying: Common Stock · 89,405 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 4, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.